Arthrosamid

Arthrosamid is a non-biodegradable, non-absorbable injectable polyacrylamide hydrogel (iPAAG) developed by Contura Orthopaedics for the treatment of knee osteoarthritis. It consists of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water. Unlike traditional pharmacological treatments, Arthrosamid acts mechanically by integrating into the synovial tissue of the inner joint capsule, providing a cushioning effect that reduces friction and pain. It is administered as a single 6 mL intra-articular injection under ultrasound guidance and has shown sustained efficacy for up to five years. It is currently approved in Europe, Canada, and New Zealand, with FDA approval pending in the United States.

Brand names

Arthrosamid

Other names

iPAAGinjectable polyacrylamide hydrogel